First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Albiruni R A Razak
No relevant relationships to disclose
Morten Mau Soerensen
No relevant relationships to disclose
Amit Mahipal
No relevant relationships to disclose
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Cindy Y. F. Yau
Research Funding - Ozmosis Research
Ulrik Niels Lassen
No relevant relationships to disclose
Dilara McCauley
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Jennifer Cooksey
No relevant relationships to disclose
David Shao Peng Tan
No relevant relationships to disclose
Jean-Richard Saint-Martin
Employment or Leadership Position - Karyopharm Therapeutics
Yossi Landesman
Employment or Leadership Position - Karyopharm Therapeutics
Gregory Pond
Research Funding - Ozmosis Research
Amit M. Oza
No relevant relationships to disclose
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Mansoor Raza Mirza
Employment or Leadership Position - Karyopharm Therapeutics
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics